Results 181 to 190 of about 30,618 (276)

Pharmacogenetics in Ophthalmology [PDF]

Proceedings of the Royal Society of Medicine, 1971
openaire   +2 more sources

Tacrolimus Concentration/Dose Ratio in Hematopoietic Cell Transplantation Recipients: An Exploratory Study of Metabolizer Phenotyping and Clinical Outcomes

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Tacrolimus pharmacokinetics shows wide interindividual variability after allogeneic hematopoietic cell transplantation (HCT), potentially influencing both effectiveness and toxicity. The concentration‐to‐dose (C/D) ratio has been proposed as a simple surrogate marker of tacrolimus metabolism, enabling patient stratification into fast or slow ...
Luiz Carlos da Costa‐Junior, Rita de Cássia Barbosa da Silva Tavares, Marina Izu, Simone Cunha Maradei, Maria Claudia Rodrigues Moreira, Marta Colares Nogueira, Décio Lerner, Teresa de Souza Fernandez, Paulo Caleb Júnior Lima Santos   +8 more
wiley   +1 more source

Genetic biomarkers associated with risk and therapeutic response in erectile dysfunction: a systematic review. [PDF]

Front Pharmacol
Ferezin LP, Kayzuka C, Paiva de Alcântara E Silva M, Tavares Peixeiro CN, Rondon-Pereira VC, Tanus-Santos JE, Lacchini R.   +6 more
europepmc   +1 more source

Severe Thiopurine‐Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Variants in TPMT and NUDT15 genes that affect thiopurine metabolism can guide personalized dosing to minimize toxicity. Decreased or no appreciable NUDT15 activity demonstrates impaired breakdown of active thiopurine metabolites which can lead to severe adverse events including potentially life‐threatening myelosuppression.
Jillian Fry, Erin C. Boone, Wendy Y. Wang, Shobana John, Lisa A. Lansdon, Midhat S. Farooqi, Byunggil Yoo, Andrea Gaedigk, Keith August, Terrie G. Flatt, Laura B. Ramsey   +10 more
wiley   +1 more source

Corrigendum to "Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort" [Curr. Res. Pharmacol. Drug Discov. 9 (2025) 100230]. [PDF]

Curr Res Pharmacol Drug Discov
Sendra L, Olivera-Pasquini GG, Zucchet EG, Genvigir FDV, Beneyto MI, Hernández-Jaras J, Herrero MJ, Aliño SF.   +7 more
europepmc   +1 more source

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines. [PDF]

Clin Pharmacol Ther
Scholefield J, Mazhindu TA, Nagy M, Twesigomwe D, Agesa G, Masimirembwa C.   +5 more
europepmc   +1 more source

Psychotropic pharmacogenetics [PDF]

Australian & New Zealand Journal of Psychiatry, 2016
openaire   +2 more sources

Extrapyramidal and anticholinergic reactions in an adolescent patient: a case for pharmacogenetic consideration. [PDF]

Biochem Med (Zagreb)
Žunić Išasegi I, Stefanović I, Okružnik Želalić M, Šimičević L, Ganoci L, Živković M, Begovac I, Božina N.   +7 more
europepmc   +1 more source

Genotype testing - reply to Sharvill. [PDF]

Br J Gen Pract
Mokbel K.
europepmc   +1 more source

ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice. [PDF]

Toxics
Božina T, Šimičević L, Ganoci L, Lovrić M, Klarica Domjanović I, Trkulja V, Božina N.   +6 more
europepmc   +1 more source